24 Facts About Sanofi

Sanofi S A is a French multinational pharmaceutical and healthcare company headquartered in Paris, France.

In 2004, Sanofi-Synthelabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers.

Sanofi is a component of the Euro Stoxx 50 stock market index.

Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical drugs principally in the prescription market, but the firm develops over-the-counter medication.

Sanofi was founded in 1973 as a subsidiary of Elf Aquitaine, when Elf Aquitaine took control of the Labaz group, a pharmaceutical company formed in 1947, by Societe Belge de l'Azote et des Produits Chimiques du Marly; Labaz developed benziodarone in 1957.

Related searches

In 1993, Sanofi made a move into the Eastern Europe market by acquiring a controlling interest in Chinoin, a Hungarian drug company that had about US$104 million in sales in 1992.

In that same year, Sanofi's made its first significant venture into the US, and strengthened its presence in Eastern Europe, by first partnering with Sterling Winthrop and then acquiring the prescription pharmaceuticals business in 1994.

Sanofi was incorporated under the laws of France in 1994, as a societe anonyme, a form of limited liability company.

Regeneron partnered the drug with Bayer Healthcare in the field of proliferative eye diseases, and under the name Eylea it was approved by the US Food and Drug Administration in 2011; after several setbacks in clinical trials, Regeneron and Sanofi got the drug approved in metastatic colorectal cancer in combination with other agents, under the brand name Zaltrap in 2012.

In January 2012, Sanofi co-invested in the $125 million Series A financing of Warp Drive Bio.

Sanofi sought support for its internal cancer research program and took on an obligation to acquire Warp Drive if certain milestones were met.

In October 2014, Sanofi's directors fired US-resident chief executive Chris Viehbacher, blaming his alleged lack of communication with the board and poor execution of his strategy.

The deal means Sanofi is one of the global consumer healthcare leaders by market share.

Sanofi agreed to produce 60 million doses of a coronavirus vaccine for the United Kingdom government in July 2020.

In January 2021, Sanofi announced it would buy the British biotech, Kymab Ltd and its potential first-in-class drug candidate – KY1005 –- for $1.

Alternate products expected to most commonly replace the recalled Sanofi devices are the EpiPens made by Mylan in the US and by Pfizer—under license from Mylan—in Canada.

Sanofi's drug was discovered by Regeneron Pharmaceuticals and is called alirocumab.

In 2013, Sanofi announced that another candidate from its collaboration with Regeneron, the monoclonal antibody against the interleukin 6 receptor, sarilumab, had better efficacy than placebo in its first Phase III trial for rheumatoid arthritis.

In January 2012, Sanofi moved its head office location to 54, Rue La Boetie in the 8th arrondissement of Paris.

On 25 October 2012, Sanofi said its earnings for the third quarter slumped as generic competitors ate into profits of its Eloxatin cancer treatment.

Sanofi planned to start Phase 1 clinical testing only in September and expected emergency use approval in the first half of 2021.

Sanofi turns out "accelerate" the development via smaller biotech firm Translate Bio, with a 425 million partnership.

Sanofi is a full member of the European Federation of Pharmaceutical Industries and Associations, Biotechnology Industry Organization, and Pharmaceutical Research and Manufacturers of America.

Sanofi's vaccine subsidiary, Sanofi Pasteur, is a member of EuropaBio.